Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioNTech 1Q Revenues Tumble | Contract Pharma

What are you searching for?

Sign in
Financial News

BioNTech 1Q Revenues Tumble

Expands pipeline and alliances amid plummeting COVID-19 vaccine sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech
1Q Revenue: €1.3 billion (revenue was €6.4 billion 1Q22)
1Q Earnings: €502.2 million (earnings were €3.7 billion 1Q22)
Comments: Results in the quarter impacted by lower commercial revenues from the supply and sales of the company’s COVID-19 vaccines worldwide. For the COVID-19 vaccine franchise, the company plans to focus on vaccine adaptation for the fall season and advancing next generation vaccine candidates and combinations.
 
BioNTech and partner OncoC4 plan to start a Phase 3 clinical trial evaluating anti-CTLA-4 antibody BNT316 (ONC-392) as monotherapy in NSCLC patients who progress after PD-1/PD-L1 treatment. The company added new class of precision therapeutics to clinical-stage oncology portfolio, with next-generation Antibody-Drug Conjugate (ADC) candidates and broadened clinical-stage infectious disease vaccine pipeline with the start of a First-in-Human clinical trial for the first mRNA-based Tuberculosis vaccine candidates. Alos, in February, BioNTech and Pfizer initiated a multicenter, randomized, controlled, dose-selection Phase 1/2 clinical trial of BNT167, the companies’ mRNA vaccine candidate against shingles. 
 
R&D expenses were €334.0 million in the quarter, compared to €285.8 million for the comparative prior year period. The change was mainly due to higher expenses incurred from progressing clinical studies for pipeline candidates. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters